| http://purl.uniprot.org/citations/22702645 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/22702645 | http://www.w3.org/2000/01/rdf-schema#comment | "CD40-soluble CD40 ligand (sCD40L) interactions might constitute an important mediator for vascular inflammation that initiates diabetic microangiopathy. Little is known about the relation between sCD40L and glycemic control. Therefore, this study aimed to evaluate sCD40L levels in patients with type 1 diabetes and its relation to microvascular complications and metabolic control. Sixty patients with type 1 diabetes were compared with 30 healthy control subjects. Detailed medical history, thorough clinical examination, and laboratory assessment of high-sensitivity C-reactive protein, glycemic control, and the presence of microvascular complications were performed. Measurement of serum sCD40L levels was done using enzyme-linked immunosorbent assay. Patients were divided into two groups according to the presence of microvascular complications. Serum sCD40L levels were significantly elevated in patients with type 1 diabetes in both groups compared with healthy controls (p < 0.001). Patients with microvascular complications had higher serum sCD40L concentrations than non-complicated cases (median, 13 000 vs. 450 pg/mL; p < 0.001). Serum sCD40L cutoff value of 530 pg/mL was able to differentiate complicated from non-complicated cases (p < 0.001). Patients with microalbuminuria or peripheral neuropathy showed higher levels of sCD40L when compared with patients without these complications (p < 0.05). Serum sCD40L levels were positively correlated with hemoglobin A1c and urinary albumin excretion (p < 0.001). We suggest that serum sCD40L levels are elevated in type 1 diabetes, particularly in patients with microvascular complications and a significant correlation with glycemic control exists. Therefore, measurement of serum sCD40L levels in poorly controlled patients would help to identify those at high risk of developing microvascular complications."xsd:string |
| http://purl.uniprot.org/citations/22702645 | http://purl.org/dc/terms/identifier | "doi:10.1111/j.1399-5448.2012.00881.x"xsd:string |
| http://purl.uniprot.org/citations/22702645 | http://purl.uniprot.org/core/author | "Ismail E.A."xsd:string |
| http://purl.uniprot.org/citations/22702645 | http://purl.uniprot.org/core/author | "Adly A.A."xsd:string |
| http://purl.uniprot.org/citations/22702645 | http://purl.uniprot.org/core/author | "El-Asrar M.A."xsd:string |
| http://purl.uniprot.org/citations/22702645 | http://purl.uniprot.org/core/date | "2012"xsd:gYear |
| http://purl.uniprot.org/citations/22702645 | http://purl.uniprot.org/core/name | "Pediatr Diabetes"xsd:string |
| http://purl.uniprot.org/citations/22702645 | http://purl.uniprot.org/core/pages | "616-624"xsd:string |
| http://purl.uniprot.org/citations/22702645 | http://purl.uniprot.org/core/title | "Soluble CD40L in children and adolescents with type 1 diabetes: relation to microvascular complications and glycemic control."xsd:string |
| http://purl.uniprot.org/citations/22702645 | http://purl.uniprot.org/core/volume | "13"xsd:string |
| http://purl.uniprot.org/citations/22702645 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/22702645 |
| http://purl.uniprot.org/citations/22702645 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/22702645 |
| http://purl.uniprot.org/uniprot/#_C1L3E0-mappedCitation-22702645 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/22702645 |
| http://purl.uniprot.org/uniprot/#_Q3L8U2-mappedCitation-22702645 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/22702645 |
| http://purl.uniprot.org/uniprot/#_Q16063-mappedCitation-22702645 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/22702645 |
| http://purl.uniprot.org/uniprot/#_P29965-mappedCitation-22702645 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/22702645 |
| http://purl.uniprot.org/uniprot/#_Q45QX2-mappedCitation-22702645 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/22702645 |
| http://purl.uniprot.org/uniprot/#_Q3LFI8-mappedCitation-22702645 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/22702645 |
| http://purl.uniprot.org/uniprot/Q3L8U2 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/22702645 |
| http://purl.uniprot.org/uniprot/Q16063 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/22702645 |
| http://purl.uniprot.org/uniprot/P29965 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/22702645 |
| http://purl.uniprot.org/uniprot/C1L3E0 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/22702645 |
| http://purl.uniprot.org/uniprot/Q45QX2 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/22702645 |
| http://purl.uniprot.org/uniprot/Q3LFI8 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/22702645 |